Grassi Investment Management buys $8,388,362 stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Grassi Investment Management scooped up 4,549 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 11, 2016. The investment management firm now holds a total of 111,060 shares of Eli Lilly and Co which is valued at $8,388,362.Eli Lilly and Co makes up approximately 1.64% of Grassi Investment Management’s portfolio.

Eli Lilly and Co closed down -0.1 points or -0.13% at $75.53 with 30,07,480 shares getting traded on Friday. Post opening the session at $75.62, the shares hit an intraday low of $75.0901 and an intraday high of $76.25 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Lynch Associatesin reduced its stake in LLY by selling 800 shares or 10.24% in the most recent quarter. The Hedge Fund company now holds 7,011 shares of LLY which is valued at $529,541. Eli Lilly and Co makes up approx 0.25% of Lynch Associatesin’s portfolio.Waverton Investment Management Ltd reduced its stake in LLY by selling 2,594 shares or 9.3% in the most recent quarter. The Hedge Fund company now holds 25,306 shares of LLY which is valued at $1,871,379. Eli Lilly and Co makes up approx 0.14% of Waverton Investment Management Ltd’s portfolio.Jlb Associates Inc reduced its stake in LLY by selling 400 shares or 1.29% in the most recent quarter. The Hedge Fund company now holds 30,630 shares of LLY which is valued at $2,265,089. Eli Lilly and Co makes up approx 0.67% of Jlb Associates Inc’s portfolio.Hollencrest Securities reduced its stake in LLY by selling 484 shares or 6.93% in the most recent quarter. The Hedge Fund company now holds 6,501 shares of LLY which is valued at $480,749. Eli Lilly and Co makes up approx 0.08% of Hollencrest Securities’s portfolio.

On the company’s financial health, Eli Lilly and Co reported $0.78 EPS for the quarter, based on the information available during the earnings call on Jan 28, 2016. Analyst had a consensus estimate of $0.78. The company had revenue of $5375.60 million for the quarter, compared to analysts expectations of $5327.26 million. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 EPS.

Many Wall Street Analysts have commented on Eli Lilly and Co. Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.